세계의 피부사상균성 조진균증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for dermatophytic onychomycosis therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global dermatophytic onychomycosis therapeutics market from 2025 to 2032.

Key Insights:

• Dermatophytic Onychomycosis Therapeutics Market Size (2025E): USD 7,074.7 Million
• Projected Market Value (2032F): USD 10,602.8 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 6.0%

Dermatophytic Onychomycosis Therapeutics Market - Report Scope:

Dermatophytic onychomycosis refers to a common fungal infection of the nail caused by dermatophytes. This condition leads to nail discoloration, thickening, and detachment, often accompanied by pain and discomfort. The market for dermatophytic onychomycosis therapeutics includes a variety of treatment options such as topical and oral antifungal agents, laser therapy, and combination treatments. The therapeutic market caters to both prescription-based and over-the-counter (OTC) products across clinical and home settings. Increasing prevalence of nail fungal infections, coupled with growing awareness and improved healthcare access, is driving market expansion. Technological advancements in drug delivery methods and the development of safer and more effective treatment options are enhancing patient compliance and market appeal.

Market Growth Drivers:

The global dermatophytic onychomycosis therapeutics market is driven by a range of factors, including the rising incidence of fungal nail infections, particularly among the aging population, diabetic patients, and individuals with compromised immune systems. Increasing awareness of foot hygiene and the demand for aesthetic nail appearance are also contributing to market growth. Furthermore, the growing availability of targeted antifungal therapies, such as terbinafine and itraconazole, and advancements in topical drug formulations have significantly improved treatment efficacy. The expansion of teledermatology and digital health platforms has further boosted diagnosis rates and treatment uptake, particularly in remote and underserved regions.

Market Restraints:

Despite promising growth prospects, the market faces several challenges. Recurrence of infection, lengthy treatment durations, and patient non-compliance with medication regimens remain significant concerns. The high cost of certain prescription treatments and limited insurance coverage in some regions can hinder access to therapy. In addition, side effects associated with systemic antifungal medications, such as liver toxicity, require careful patient monitoring, which may deter both patients and providers. Regulatory hurdles for product approval and the need for long-term clinical trials also pose barriers to market entry for new players.

Market Opportunities:

The dermatophytic onychomycosis therapeutics market offers numerous growth opportunities driven by innovation and unmet clinical needs. The development of novel antifungal agents with enhanced penetration and reduced toxicity is a key area of focus for pharmaceutical companies. Additionally, the rising popularity of laser-based and photodynamic therapies presents non-invasive alternatives with minimal side effects. Increased investment in R&D, combined with strategic collaborations between pharmaceutical companies and dermatology clinics, is expected to foster the introduction of next-generation treatments. Emerging economies present untapped potential due to rising disposable income, urbanization, and improving healthcare infrastructure.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the dermatophytic onychomycosis therapeutics market globally?
• Which treatment modalities are gaining traction among patients and providers across various healthcare settings?
• How are technological innovations impacting treatment effectiveness and patient adherence in onychomycosis management?
• Who are the major players in this therapeutic space, and what strategies are they adopting to maintain competitiveness?
• What are the upcoming trends and future outlook for the global dermatophytic onychomycosis therapeutics market?

Competitive Intelligence and Business Strategy:

Key players in the global dermatophytic onychomycosis therapeutics market, including Pfizer Inc., Novartis AG, Bausch Health Companies Inc., and Moberg Pharma AB, focus on expanding their product portfolios through R&D, strategic partnerships, and geographical expansion. Companies are also investing in developing user-friendly topical treatments and oral medications with shorter treatment durations and improved efficacy. Collaborations with dermatology clinics and retail pharmacies, along with patient education campaigns, are enhancing awareness and improving treatment outcomes. Digital marketing and e-commerce platforms are increasingly leveraged to improve product accessibility and consumer reach.

Key Companies Profiled:

• Bausch Health
• Galderma S.A.
• Novartis AG
• Pfizer, Inc.
• Moberg Pharma AB
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Medimetriks Pharmaceuticals, Inc.
• Sanofi S.A.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Cardinal Health Inc.
• Viatris Inc.
• Almirall, S.A
• Vanda Pharmaceuticals Inc.
• Others

Market Segmentation

By Treatment Type

• Drug-Based Treatment

* Topical Antifungals

* Oral Antifungals

• Laser Therapy
• Photodynamic Therapy
• Combination Therapy

By Indication

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

By End-user

• Institutional Sales
• Hospitals
• Dermatology Clinics
• Retail Sales
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies & Online Sales

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Treatment Adoption Analysis
• 3.3. Disease Epidemiology
• 3.4. Pipeline Analysis
• 3.5. Reimbursement Scenario
• 3.6. Value Chain Analysis
• 3.7. Key Deals and Mergers
• 3.8. PESTLE Analysis
• 3.9. Porter's Five Force Analysis

4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Treatment Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 4.3.3.1. Drug-Based Treatment
      • 4.3.3.1.1. Topical Antifungals
      • 4.3.3.1.2. Oral Antifungals
    • 4.3.3.2. Laser Therapy
    • 4.3.3.3. Photodynamic Therapy
    • 4.3.3.4. Combination Therapy
  • 4.3.4. Market Attractiveness Analysis: Treatment Type
• 4.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Indication
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.4.3.1. Distal Subungual Onychomycosis
    • 4.4.3.2. White Superficial Onychomycosis
    • 4.4.3.3. Proximal Subungual Onychomycosis
    • 4.4.3.4. Candidal Onychomycosis
    • 4.4.3.5. Total Dystrophic Onychomycosis
  • 4.4.4. Market Attractiveness Analysis: Indication
• 4.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.5.3.1. Institutional Sales
      • 4.5.3.1.1. Hospitals
      • 4.5.3.1.2. Dermatology Clinics
    • 4.5.3.2. Retail Sales
      • 4.5.3.2.1. Retail Pharmacies
      • 4.5.3.2.2. Drug Stores
      • 4.5.3.2.3. Mail Order Pharmacies & Online Sales
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Treatment Type
  • 6.2.3. By Indication
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 6.4.1. Drug-Based Treatment
    • 6.4.1.1. Topical Antifungals
    • 6.4.1.2. Oral Antifungals
  • 6.4.2. Laser Therapy
  • 6.4.3. Photodynamic Therapy
  • 6.4.4. Combination Therapy
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.5.1. Distal Subungual Onychomycosis
  • 6.5.2. White Superficial Onychomycosis
  • 6.5.3. Proximal Subungual Onychomycosis
  • 6.5.4. Candidal Onychomycosis
  • 6.5.5. Total Dystrophic Onychomycosis
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.6.1. Institutional Sales
    • 6.6.1.1. Hospitals
    • 6.6.1.2. Dermatology Clinics
  • 6.6.2. Retail Sales
    • 6.6.2.1. Retail Pharmacies
    • 6.6.2.2. Drug Stores
    • 6.6.2.3. Mail Order Pharmacies & Online Sales
• 6.7. Market Attractiveness Analysis

7. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Treatment Type
  • 7.2.3. By Indication
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 7.4.1. Drug-Based Treatment
    • 7.4.1.1. Topical Antifungals
    • 7.4.1.2. Oral Antifungals
  • 7.4.2. Laser Therapy
  • 7.4.3. Photodynamic Therapy
  • 7.4.4. Combination Therapy
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.5.1. Distal Subungual Onychomycosis
  • 7.5.2. White Superficial Onychomycosis
  • 7.5.3. Proximal Subungual Onychomycosis
  • 7.5.4. Candidal Onychomycosis
  • 7.5.5. Total Dystrophic Onychomycosis
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.6.1. Institutional Sales
    • 7.6.1.1. Hospitals
    • 7.6.1.2. Dermatology Clinics
  • 7.6.2. Retail Sales
    • 7.6.2.1. Retail Pharmacies
    • 7.6.2.2. Drug Stores
    • 7.6.2.3. Mail Order Pharmacies & Online Sales
• 7.7. Market Attractiveness Analysis

8. East Asia Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Treatment Type
  • 8.2.3. By Indication
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 8.4.1. Drug-Based Treatment
    • 8.4.1.1. Topical Antifungals
    • 8.4.1.2. Oral Antifungals
  • 8.4.2. Laser Therapy
  • 8.4.3. Photodynamic Therapy
  • 8.4.4. Combination Therapy
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.5.1. Distal Subungual Onychomycosis
  • 8.5.2. White Superficial Onychomycosis
  • 8.5.3. Proximal Subungual Onychomycosis
  • 8.5.4. Candidal Onychomycosis
  • 8.5.5. Total Dystrophic Onychomycosis
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.6.1. Institutional Sales
    • 8.6.1.1. Hospitals
    • 8.6.1.2. Dermatology Clinics
  • 8.6.2. Retail Sales
    • 8.6.2.1. Retail Pharmacies
    • 8.6.2.2. Drug Stores
    • 8.6.2.3. Mail Order Pharmacies & Online Sales
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Treatment Type
  • 9.2.3. By Indication
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 9.4.1. Drug-Based Treatment
    • 9.4.1.1. Topical Antifungals
    • 9.4.1.2. Oral Antifungals
  • 9.4.2. Laser Therapy
  • 9.4.3. Photodynamic Therapy
  • 9.4.4. Combination Therapy
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.5.1. Distal Subungual Onychomycosis
  • 9.5.2. White Superficial Onychomycosis
  • 9.5.3. Proximal Subungual Onychomycosis
  • 9.5.4. Candidal Onychomycosis
  • 9.5.5. Total Dystrophic Onychomycosis
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.6.1. Institutional Sales
    • 9.6.1.1. Hospitals
    • 9.6.1.2. Dermatology Clinics
  • 9.6.2. Retail Sales
    • 9.6.2.1. Retail Pharmacies
    • 9.6.2.2. Drug Stores
    • 9.6.2.3. Mail Order Pharmacies & Online Sales
• 9.7. Market Attractiveness Analysis

10. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Treatment Type
  • 10.2.3. By Indication
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 10.4.1. Drug-Based Treatment
    • 10.4.1.1. Topical Antifungals
    • 10.4.1.2. Oral Antifungals
  • 10.4.2. Laser Therapy
  • 10.4.3. Photodynamic Therapy
  • 10.4.4. Combination Therapy
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.5.1. Distal Subungual Onychomycosis
  • 10.5.2. White Superficial Onychomycosis
  • 10.5.3. Proximal Subungual Onychomycosis
  • 10.5.4. Candidal Onychomycosis
  • 10.5.5. Total Dystrophic Onychomycosis
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.6.1. Institutional Sales
    • 10.6.1.1. Hospitals
    • 10.6.1.2. Dermatology Clinics
  • 10.6.2. Retail Sales
    • 10.6.2.1. Retail Pharmacies
    • 10.6.2.2. Drug Stores
    • 10.6.2.3. Mail Order Pharmacies & Online Sales
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Treatment Type
  • 11.2.3. By Indication
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 11.4.1. Drug-Based Treatment
    • 11.4.1.1. Topical Antifungals
    • 11.4.1.2. Oral Antifungals
  • 11.4.2. Laser Therapy
  • 11.4.3. Photodynamic Therapy
  • 11.4.4. Combination Therapy
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.5.1. Distal Subungual Onychomycosis
  • 11.5.2. White Superficial Onychomycosis
  • 11.5.3. Proximal Subungual Onychomycosis
  • 11.5.4. Candidal Onychomycosis
  • 11.5.5. Total Dystrophic Onychomycosis
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.6.1. Institutional Sales
    • 11.6.1.1. Hospitals
    • 11.6.1.2. Dermatology Clinics
  • 11.6.2. Retail Sales
    • 11.6.2.1. Retail Pharmacies
    • 11.6.2.2. Drug Stores
    • 11.6.2.3. Mail Order Pharmacies & Online Sales
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Structure
  • 12.1.1. Competition Intensity Mapping By Market
  • 12.1.2. Competition Dashboard
• 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.2.1. Bausch Health
    • 12.2.1.1. Overview
    • 12.2.1.2. Segments and Treatment Types
    • 12.2.1.3. Key Financials
    • 12.2.1.4. Market Developments
    • 12.2.1.5. Market Strategy
  • 12.2.2. Galderma S.A.
  • 12.2.3. Novartis AG
  • 12.2.4. Pfizer, Inc.
  • 12.2.5. Moberg Pharma AB
  • 12.2.6. Bayer AG
  • 12.2.7. Dr. Reddy's Laboratories Ltd.
  • 12.2.8. Cipla Ltd.
  • 12.2.9. Medimetriks Pharmaceuticals, Inc.
  • 12.2.10. Sanofi S.A.
  • 12.2.11. GlaxoSmithKline Plc.
  • 12.2.12. Teva Pharmaceutical industries Ltd.
  • 12.2.13. Cardinal Health Inc.
  • 12.2.14. Viatris Inc.
  • 12.2.15. Almirall, S.A
  • 12.2.16. Vanda Pharmaceuticals Inc.
  • 12.2.17. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations